Table 1.
Patient Demographic and Clinical Characteristics
| Characteristic | CIS Plus RT (n = 194) |
CIS, TPZ, and RT (n = 185) |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Age, years | ||||
| ≤ 30 | 7 | 3.6 | 10 | 5.4 |
| 31-40 | 41 | 21.1 | 37 | 20.0 |
| 41-50 | 65 | 33.5 | 61 | 33.0 |
| 51-60 | 53 | 27.3 | 48 | 25.9 |
| 61-70 | 20 | 10.3 | 23 | 12.4 |
| > 70 | 8 | 4.1 | 6 | 3.2 |
| Median | 48.0 | 47.0 | ||
| Race | ||||
| Black | 43 | 22.2 | 30 | 16.2 |
| American Indian | 8 | 4.1 | 2 | 1.1 |
| Pacific Islander | 1 | 0.5 | 2 | 1.1 |
| Asian | 6 | 3.1 | 10 | 5.4 |
| White | 129 | 66.5 | 134 | 72.4 |
| Unknown | 7 | 3.6 | 7 | 3.8 |
| Ethnicity | ||||
| Hispanic | 20 | 10.3 | 24 | 13.0 |
| Non-Hispanic | 161 | 83.0 | 138 | 74.6 |
| Unknown/not specified | 13 | 6.7 | 23 | 12.4 |
| Performance status | ||||
| 0 | 147 | 75.8 | 141 | 76.2 |
| 1 | 46 | 23.7 | 41 | 22.2 |
| 2 | 1 | 0.5 | 2 | 1.1 |
| 3 | 0 | 0.0 | 1 | 0.5 |
| Tumor grade | ||||
| 1 | 8 | 4.1 | 12 | 6.5 |
| 2 | 105 | 54.1 | 103 | 55.7 |
| 3 | 78 | 40.2 | 67 | 36.2 |
| Not graded | 3 | 1.5 | 3 | 1.6 |
| Disease stage | ||||
| IB | 33 | 17.0 | 32 | 17.3 |
| IIA | 11 | 5.7 | 12 | 6.5 |
| IIB | 93 | 47.9 | 82 | 44.3 |
| IIIB | 51 | 26.3 | 52 | 28.1 |
| IVA | 6 | 3.1 | 7 | 3.8 |
| Cell type | ||||
| Squamous cell carcinoma | 164 | 84.5 | 158 | 85.4 |
| Adenocarcinoma, unspecified | 15 | 7.7 | 18 | 9.7 |
| Adenosquamous carcinoma | 11 | 5.7 | 5 | 2.7 |
| Other | 4 | 2.1 | 4 | 2.2 |
| Para-aortic lymph node | ||||
| Not sampled | 25 | 12.9 | 33 | 17.8 |
| Sampled | 169 | 87.1 | 152 | 82.2 |
| Brachytherapy | ||||
| None | 4 | 2.1 | 5 | 2.7 |
| Low-dose rate | 52 | 26.8 | 51 | 27.6 |
| High-dose rate | 138 | 71.1 | 129 | 69.7 |
| Cooperative group | ||||
| GOG | 167 | 86.1 | 167 | 90.3 |
| NCIC | 24 | 12.4 | 17 | 9.2 |
| Other | 3 | 1.5 | 1 | 0.5 |
Abbreviations: CIS, cisplatin; GOG, Gynecologic Oncology Group; NCIC, National Cancer Institute of Canada; RT, radiotherapy; TPZ, tirapazamine.